Eradication of Chronic Myeloid Leukemia Stem Cells: A Novel Mathematical Model Predicts No Therapeutic Benefit of Adding G-CSF to Imatinib
暂无分享,去创建一个
Franziska Michor | Jasmine Foo | Tessa Holyoake | Mark W. Drummond | Bayard Clarkson | F. Michor | T. Holyoake | B. Clarkson | J. Foo | M. Drummond
[1] Andreas Trumpp,et al. Hematopoietic Stem Cells Reversibly Switch from Dormancy to Self-Renewal during Homeostasis and Repair , 2008, Cell.
[2] Dominik Wodarz,et al. Drug resistance in cancer: principles of emergence and prevention. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[3] G. Tjønnfjord,et al. Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia , 2004, European journal of haematology.
[4] A. Tsukamoto,et al. The unexpected G0/G1 cell cycle status of mobilized hematopoietic stem cells from peripheral blood. , 1997, Blood.
[5] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[6] T. Holyoake,et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. , 2002, Blood.
[7] D. Scadden,et al. Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation , 2008, Nature Reviews Genetics.
[8] J. Kuriyan,et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.
[9] W. Thilly,et al. A statistical model to estimate variance in long term-low dose mutation assays: testing of the model in a human lymphoblastoid mutation assay. , 1989, Mutation research.
[10] I. Weissman,et al. Stem cells, cancer, and cancer stem cells , 2001, Nature.
[11] Doron Levy,et al. Dynamics and Potential Impact of the Immune Response to Chronic Myelogenous Leukemia , 2008, PLoS Comput. Biol..
[12] S. Forman,et al. Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. , 2007, Cancer research.
[13] R. Gale,et al. Chronic myeloid leukemia. , 1992, The American journal of medicine.
[14] J. Cayuela,et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. , 2005, Blood.
[15] T. Suda,et al. Maintenance of Quiescent Hematopoietic Stem Cells in the Osteoblastic Niche , 2007, Annals of the New York Academy of Sciences.
[16] Martin A Nowak,et al. The age incidence of chronic myeloid leukemia can be explained by a one-mutation model , 2006, Proceedings of the National Academy of Sciences.
[17] Franziska Michor,et al. Successful Therapy Must Eradicate Cancer Stem Cells , 2006, Stem cells.
[18] E. Orlandi,et al. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. , 2005, Haematologica.
[19] A. Strife,et al. Biology of chronic myelogenous leukemia: is discordant maturation the primary defect? , 1988, Seminars in hematology.
[20] R. Herrmann,et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. , 2002, Blood.
[21] Martin A. Nowak,et al. Dynamics of chronic myeloid leukaemia , 2005, Nature.
[22] C. Eaves,et al. Human hematopoietic stem cells stimulated to proliferate in vitro lose engraftment potential during their S/G(2)/M transit and do not reenter G(0). , 2000, Blood.
[23] F. Michor. Chronic Myeloid Leukemia Blast Crisis Arises from Progenitors , 2007, Stem cells.
[24] Rudolf Jaenisch,et al. Analysis of histone 2B-GFP retention reveals slowly cycling hematopoietic stem cells , 2009, Nature Biotechnology.
[25] D. Wodarz,et al. Effect of cellular quiescence on the success of targeted CML therapy , 2022 .
[26] B. Druker,et al. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. , 2004, Leukemia research.
[27] Yoshiya Tanaka,et al. Imatinib mesylate‐sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: Report of two cases , 2004, American journal of hematology.
[28] Claude Preudhomme,et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. , 2002, Blood.
[29] C. Eaves,et al. Intermittent Exposure of Primitive Quiescent Chronic Myeloid Leukemia Cells to Granulocyte-Colony Stimulating Factor In vitro Promotes their Elimination by Imatinib Mesylate , 2006, Clinical Cancer Research.
[30] AC Eaves,et al. Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia , 2002, Leukemia.
[31] R. Pyatt,et al. Functional heterogeneity of human CD34(+) cells isolated in subcompartments of the G0 /G1 phase of the cell cycle. , 1997, Blood.
[32] Susan Branford,et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. , 2003, Blood.
[33] Laurie E Ailles,et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. , 2004, The New England journal of medicine.
[34] W. R. Bruce,et al. A Quantitative Assay for the Number of Murine Lymphoma Cells capable of Proliferation in vivo , 1963, Nature.
[35] Ben D. Chen,et al. The Unexpected G 0 / G 1 Cell Cycle Status of Mobilized Hematopoietic Stem Cells From Peripheral Blood , 1997 .
[36] Ingo Roeder,et al. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications , 2006, Nature Medicine.
[37] J. Dick,et al. Cancer stem cells: lessons from leukemia. , 2005, Trends in cell biology.
[38] J. Dick,et al. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity , 2004, Nature Immunology.
[39] J. Apperley. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. , 2007, The Lancet. Oncology.
[40] M. Caligiuri,et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.
[41] R. Clark,et al. A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response , 2009, Leukemia.
[42] C. Eaves,et al. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. , 1999, Blood.
[43] B. Williams,et al. Quiescence, cycling, and turnover in the primitive hematopoietic stem cell compartment. , 1997, Experimental hematology.
[44] H. Kantarjian,et al. Discontinuation of imatinib therapy after achieving a molecular response. , 2004, Blood.
[45] C. Eaves,et al. Quantitation of the quiescent fraction of long-term culture-initiating cells in normal human blood and marrow and the kinetics of their growth factor-stimulated entry into S-phase in vitro. , 1995, Blood.
[46] Irving L. Weissman,et al. Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates , 2005, The Journal of experimental medicine.
[47] R. Pyatt,et al. Functional Heterogeneity of Human CD34+ Cells Isolated in Subcompartments of the G0 /G1 Phase of the Cell Cycle , 1997 .
[48] T. Flores,et al. A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. , 2000, Blood.
[49] C. Eaves,et al. Changes in the Proliferative Activity of Human Hematopoietic Stem Cells in NOD/SCID Mice and Enhancement of Their Transplantability after In Vivo Treatment with Cell Cycle Inhibitors , 2002, The Journal of experimental medicine.
[50] Christine Barett,et al. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. , 2006, Blood.
[51] J. Rowley. A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.
[52] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.